IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

NCT01885897 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Myelodysplastic Syndromes (MDS)
Lymphoma
Myeloma
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelogenous Leukemia (CML)

Interventions

BIOLOGICAL: ALT-803

Sponsor

Masonic Cancer Center, University of Minnesota